M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Seattle Genetics' collaboration with AbbVie on Antibody-Drug Conjugate further expanded

Biotechnology company Seattle Genetics Inc (Nasdaq:SGEN) announced on Wednesday the further expansion of its antibody-drug conjugate (ADC) collaboration with AbbVie (NYSE:ABBV).

Under this expanded agreement, AbbVie will pay an upfront fee of USD25m for additional rights to utilise Seattle...  

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search